Skip to content

US relies on nasal spray against COVID-19


The U.S. Department of Health and Human Services (HHS) announced Thursday that it will provide up to $500 million for mid-stage clinical trials to evaluate vaccines administered as nasal sprays or pills designed to protect against symptomatic COVID-19.

The funding is part of Project NextGen, a $5 billion initiative led by the Biomedical Advanced Research and Development Authority (BARDA) to advance a range of new, innovative vaccines and therapeutics intended to offer broader and longer-lasting protection against COVID-19 infections.

author avatar
LabNews Media LLC
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu